Kyntra Bio, Inc. (KYNB)
Develops drugs to treat cancer, anemia, and kidney disease
$7.00-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+1.6%
The outlook
KYNB is trading near $7, well below both its 50- and 200-day moving averages, and sits near the low end of its 52-week range. Analyst coverage is sparse with a bearish lean overall, though the average price target implies substantial upside from current levels. The technical setup reflects weakness despite the optimistic target gap.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +457% vs current price
Analyst price target
~12-month · 2 analysts$39.00average target+457.1% vs now
Now $7.00
Low $35.00High $43.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$28.3M
52-wk high
$12.60
52-wk low
$6.32
50-day avg
$7.06
200-day avg
$8.06
Trailing P/E
—